Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease?: Implications for therapeutic blockade of the renin-angiotensin system

被引：139
作者：
Lévy, BI [1 ]
机构：
[1] Univ Paris 07, IFR Circulat Lariboisiere, Hop Lariboisiere, INSERM,U541, F-75475 Paris 10, France
来源：
CIRCULATION | 2004年 / 109卷 / 01期
关键词：
receptors; angiotensin; cardiovascular diseases; hypertrophy;
D O I：
10.1161/01.CIR.0000096609.73772.C5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：8 / 13
页数：6
相关论文
共 54 条
  • [31] Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats
    Matrougui, K
    Lévy, BI
    Henrion, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (03) : 521 - 526
  • [32] Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
    Matsubara, H
    [J]. CIRCULATION RESEARCH, 1998, 83 (12) : 1182 - 1191
  • [33] Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis
    Miura, SI
    Karnik, SS
    [J]. EMBO JOURNAL, 2000, 19 (15) : 4026 - 4035
  • [34] Moudgil R, 2002, CAN J CARDIOL, V18, P1107
  • [35] Opposing actions of angiotensin II on microvascular growth and arterial blood pressure
    Munzenmaier, DH
    Greene, AS
    [J]. HYPERTENSION, 1996, 27 (03) : 760 - 765
  • [36] RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial (Retracted article. See vol. 374, pg. 1226, 2009)
    Nakao, N
    Yoshimura, A
    Morita, H
    Takada, M
    Kayano, T
    Ideura, T
    [J]. LANCET, 2003, 361 (9352) : 117 - 124
  • [37] Enhanced angiotensin II activity in heart failure - Reevaluation of the counterregulatory hypothesis of receptor subtypes
    Opie, LH
    Sack, MN
    [J]. CIRCULATION RESEARCH, 2001, 88 (07) : 654 - 658
  • [38] Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats
    Otsuka, S
    Sugano, M
    Makino, N
    Sawada, S
    Hata, T
    Niho, Y
    [J]. HYPERTENSION, 1998, 32 (03) : 467 - 472
  • [39] Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Pfeffer, MA
    McMurray, JJV
    Velazquez, EJ
    Rouleau, JL
    Kober, L
    Maggioni, AP
    Solomon, SD
    Swedberg, K
    Van de Werf, F
    White, H
    Leimberger, JD
    Henis, M
    Edwards, S
    Zelenkofske, S
    Sellers, MA
    Califf, RM
    Aylward, P
    Armstrong, P
    Barvik, S
    Belenkov, Y
    Dalby, A
    Diaz, R
    Drexler, H
    Ertl, G
    Francis, G
    Hampton, J
    Harsanyi, A
    Kvasnicka, J
    Mareev, V
    Marin-Neto, J
    Murin, J
    Myers, M
    Nordlander, R
    Opolski, G
    Soler-Soler, J
    Spac, J
    Stefenelli, T
    Sugrue, D
    Van Gilst, W
    Varshavsky, S
    Weaver, D
    Zannad, F
    Aguilar, D
    Alvarez, A
    Al-Taweel, M
    Anavekar, N
    Finn, P
    Lopez-Jimenez, F
    Mercier, R
    Lewis, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) : 1893 - 1906
  • [40] Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II
    Pitt, B
    Poole-Wilson, PA
    Segal, R
    Martinez, FA
    Dickstein, K
    Camm, AJ
    Konstam, MA
    Riegger, G
    Klinger, GH
    Neaton, J
    Sharma, D
    Thiyagarajan, B
    [J]. LANCET, 2000, 355 (9215) : 1582 - 1587
123456